Nectar Lifesciences Ltd has announced the sale of its active pharmaceutical ingredients and formulations business to Ceph Lifesciences for ₹1,270 crores, along with its menthol business for ₹20 crores, as part of their restructuring plan aimed at strengthening finances and fostering growth, expected to complete by September 20, 2025.